Cohance Lifesciences Latest Share Price (COHANCE)
TODAY IN ONE LINE
COHANCE fell 2.6% on above-average volume (3.0x avg), lagging Nifty's 0.1% move.
With a market cap of ₹17,743.46 Cr., it trades at a P/E of 167.27. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Cohance Lifesciences flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Healthy Operating MarginsOPM is structurally strong at 18.8%
- ●High Promoter HoldingPromoters hold 57.5% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.10x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 89.0% YoY
- ●Sales ContractionQuarterly sales dropped 26.3% YoY
- ●Poor Capital ReturnsLow ROE of 7.0%
- ●Expensive ValuationTrading at a high P/E ratio of 96.5x
- ●Promoter SellingPromoter holding decreased by 8.92% QoQ
- ●Rising Receivables vs SalesReceivables grew 89.7% outpacing sales growth of 13.9%
Latest Cohance Lifesciences News
What changed recently?
Recent events, corporate actions, and announcements.
Cohance Lifesciences Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Cohance Lifesciences Limited, framed against the sector median so the premium or discount is obvious at a glance.
Cohance Lifesciences Limited trades at a P/E of 167.27× and P/B of 4.55×, against the Healthcare sector median P/E of 45.44×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Cohance Lifesciences Limited technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for Cohance Lifesciences Limited — derived from the latest tape, not yesterday's close.
Cohance Lifesciences Limited last traded at ₹463 with an intraday range of ₹457–₹481.05 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹463.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 525.13 | +62.13 | +13.42% |
| R3 | 501.08 | +38.08 | +8.23% |
| R2 | 491.07 | +28.07 | +6.06% |
| R1 | 477.03 | +14.03 | +3.03% |
| PIVOT | 467.02 | 4.02 | 0.87% |
| CURRENT | 463.00 | — | — |
| S1 | 452.98 | -10.02 | -2.16% |
| S2 | 442.97 | -20.03 | -4.33% |
| S3 | 428.93 | -34.07 | -7.36% |
| S4 | 404.88 | -58.12 | -12.55% |
COHANCE is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹469.1–₹481.05
Trading Inside opening range
Cohance Lifesciences Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Cohance Lifesciences Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Cohance Lifesciences Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹17,743.46 Cr. and reported EPS of ₹2.77.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,198 | 2,269 ▲ 89.4% |
| Sales Growth YoY %Derived | 13.91% | 89.43% |
| Other Income | 59 | 34 ▼ 41.8% |
| Total Income | 1,256 | 2,303 ▲ 83.3% |
| 305 | 663 ▲ 117.0% | |
| Gross ProfitDerived | 892 | 1,606 ▲ 80.0% |
| Gross Margin %Derived | 74.51% | 70.79% |
| 517 | 1,179 ▲ 128.0% | |
| EBITDA (Operating Profit)Derived | 375 | 427 ▲ 13.8% |
| OPM %Derived | 31.33% | 18.82% |
| 90 | 195 ▲ 117.2% | |
| Profit Before Tax (PBT) | 344 | 207 ▼ 39.8% |
| 79 | 57 ▼ 28.1% | |
| Effective Tax %Derived | 23.01% | 27.49% |
| Total Profit for Period | 265 | 150 ▼ 43.3% |
| Less: Non-controlling Interests | -3 | -29 ▼ 839.0% |
| Net Profit (Owner's PAT)Derived | 268 | 179 ▼ 33.1% |
| Net Profit Margin %Derived | 22.37% | 7.90% |
| PAT Growth YoY %Derived | -10.79% | -33.09% |
| Earnings Per Share (EPS ₹) | 10.52 | 4.68 ▼ 55.5% |
| Diluted Shares Outstanding (Cr) | 25 | 38 ▲ 50.3% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | 13 | 99 ▲ 653.7% |
| Total Expenses (incl. D&A & Interest) | 912 | 2,096 ▲ 129.7% |
| Material Cost % of RevenueDerived | 18.59% | 31.09% |
| Employee Cost % of RevenueDerived | 20.84% | 22.38% |
| Other Cost % of RevenueDerived | 22.34% | 29.59% |
| Interest Coverage (x)Derived | 24.11x | 6.44x |
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 834 | 1,010 ▲ 21.1% | 1,320 ▲ 30.8% | 1,340 ▲ 1.5% | 1,051 ▼ 21.6% | 1,198 ▲ 13.9% | 2,269 ▲ 89.4% | |
| Sales Growth YoY %Derived | — | 21.10% | 30.75% | 1.52% | -21.56% | 13.91% | 89.43% | |
| Other Income | 18 | 14 ▼ 21.4% | 92 ▲ 548.9% | 46 ▼ 49.8% | 62 ▲ 33.5% | 59 ▼ 5.4% | 34 ▼ 41.8% | |
| Total Income | 852 | 1,024 ▲ 20.2% | 1,413 ▲ 38.0% | 1,387 ▼ 1.8% | 1,113 ▼ 19.7% | 1,256 ▲ 12.8% | 2,303 ▲ 83.3% | |
229 | 302 ▲ 31.7% | 399 ▲ 32.2% | 409 ▲ 2.5% | 315 ▼ 23.0% | 305 ▼ 3.1% | 663 ▲ 117.0% | ||
| Gross ProfitDerived | 605 | 708 ▲ 17.1% | 921 ▲ 30.1% | 931 ▲ 1.1% | 736 ▼ 20.9% | 892 ▲ 21.2% | 1,606 ▲ 80.0% | |
| Gross Margin %Derived | 72.51% | 70.10% | 69.77% | 69.48% | 70.04% | 74.51% | 70.79% | |
219 | 267 ▲ 21.8% | 342 ▲ 27.8% | 365 ▲ 6.7% | 331 ▼ 9.4% | 517 ▲ 56.5% | 1,179 ▲ 128.0% | ||
| EBITDA (Operating Profit)Derived | 385 | 440 ▲ 14.4% | 579 ▲ 31.5% | 567 ▼ 2.2% | 406 ▼ 28.4% | 375 ▼ 7.5% | 427 ▲ 13.8% | |
| OPM %Derived | 46.19% | 43.62% | 43.89% | 42.27% | 38.60% | 31.33% | 18.82% | |
47 | 41 ▼ 13.1% | 45 ▲ 11.2% | 53 ▲ 17.3% | 62 ▲ 16.7% | 90 ▲ 44.8% | 195 ▲ 117.2% | ||
| Profit Before Tax (PBT) | 356 | 414 ▲ 16.2% | 626 ▲ 51.3% | 560 ▼ 10.7% | 406 ▼ 27.5% | 344 ▼ 15.2% | 207 ▼ 39.8% | |
88 | 105 ▲ 20.4% | 214 ▲ 103.0% | 148 ▼ 30.6% | 105 ▼ 29.0% | 79 ▼ 24.9% | 57 ▼ 28.1% | ||
| Effective Tax %Derived | 24.56% | 25.45% | 34.12% | 26.52% | 25.98% | 23.01% | 27.49% | |
| Total Profit for Period | 317 | 362 ▲ 14.3% | 454 ▲ 25.2% | 411 ▼ 9.4% | 300 ▼ 27.0% | 265 ▼ 11.8% | 150 ▼ 43.3% | |
| Less: Non-controlling Interests | — | — | — | — | — | -3 | -29 ▼ 839.0% | |
| Net Profit (Owner's PAT)Derived | 317 | 362 ▲ 14.3% | 454 ▲ 25.2% | 411 ▼ 9.4% | 300 ▼ 27.0% | 268 ▼ 10.8% | 179 ▼ 33.1% | |
| Net Profit Margin %Derived | 38.02% | 35.89% | 34.37% | 30.69% | 28.56% | 22.37% | 7.90% | |
| PAT Growth YoY %Derived | — | 14.30% | 25.24% | -9.37% | -26.99% | -10.79% | -33.09% | |
| Earnings Per Share (EPS ₹) | 12.45 | 14.23 ▲ 14.3% | 17.83 ▲ 25.3% | 16.16 ▼ 9.4% | 11.80 ▼ 27.0% | 10.52 ▼ 10.8% | 4.68 ▼ 55.5% | |
| Diluted Shares Outstanding (Cr) | 25 | 25 ▲ 0.0% | 25 ▲ 0.0% | 25 ▲ 0.0% | 25 ▲ 0.0% | 25 ▲ 0.0% | 38 ▲ 50.3% | |
| Share of Profit from Associates/JVs | 48 | 54 ▲ 11.5% | 41 ▼ 23.5% | — ▼ 100.0% | — | — | — | |
| Other Comprehensive Income (Net of Tax) | -1 | -1 ▼ 2.3% | -1 ▲ 8.9% | -0 ▲ 75.6% | 13 ▲ 7183.7% | 13 ▼ 0.5% | 99 ▲ 653.7% | |
| Total Expenses (incl. D&A & Interest) | 496 | 610 ▲ 23.1% | 786 ▲ 28.9% | 827 ▲ 5.2% | 708 ▼ 14.4% | 912 ▲ 28.9% | 2,096 ▲ 129.7% | |
| Material Cost % of RevenueDerived | 28.81% | 30.73% | 34.80% | 32.09% | 25.29% | 18.59% | 31.09% | |
| Employee Cost % of RevenueDerived | 8.84% | 7.55% | 7.61% | 8.25% | 12.93% | 20.84% | 22.38% | |
| Other Cost % of RevenueDerived | 17.48% | 18.92% | 18.27% | 18.96% | 18.51% | 22.34% | 29.59% | |
| Interest Coverage (x)Derived | 15.66x | 44.71x | 86.72x | 95.43x | 47.14x | 24.11x | 6.44x |
Cohance Lifesciences segment analysis : revenue and profit mix.
Disclosed business segments at Cohance Lifesciences with their share of revenue and profit, switchable between consolidated and standalone reporting.
Cohance Lifesciences discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Cohance Lifesciences Limited.
Our AI distills the core fundamental drivers supporting Cohance Lifesciences Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Cohance Lifesciences Limited's investment case rests on 9 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Low debt-to-equity ratio 0.0010 ensures fortress balance sheet and financial flexibility.
Promoter holding 57.49% signals strong insider confidence and long-term commitment.
Quarterly sales grew 12.6% YoY, demonstrating resilient near-term revenue momentum.
Operating margin 10.56% reflects moderate cost control in pharmaceutical manufacturing.
Institutional investor holdings increased to 20.8%, boosting market confidence signals.
Key Risks.
Latest quarterly EPS declined 83.8% YoY despite revenue growth, earnings weakness evident.
TTM EPS declined 89.0% YoY, reflecting severe earnings contraction and profitability crisis.
Quarterly PAT fell 86.6% YoY, indicating significant operational profitability deterioration.
Net margin 7.9% lags peer benchmarks, limiting reinvestment and shareholder return capacity.
No dividend yield deters income-seeking investors from holding shares long-term.
Flip Conditions.
Valuation risk. a P/E above 217 (~4.8× the sector multiple of 45.4) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Cohance Lifesciences Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Cohance Lifesciences Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Cohance Lifesciences Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Cohance Lifesciences Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
Cohance Lifesciences Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Cohance Lifesciences Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Cohance Lifesciences Limited stood at 38.2% of traded volume, against a 20-day average of 46.0%.
Cohance Lifesciences announcements: results, concalls, ratings, M&A.
Filings Cohance Lifesciences sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Cohance Lifesciences files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 160 documents below.
Credit Rating- Others
Cohance Lifesciences Limited has informed the Exchange about Credit Rating- Others
Analysts/Institutional Investor Meet/Con. Call Updates
Cohance Lifesciences Limited has informed the Exchange about Transcript
Copy of Newspaper Publication
Cohance Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Analysts/Institutional Investor Meet/Con. Call Updates
Cohance Lifesciences Limited has informed the Exchange about Link of Recording
General Updates
Cohance Lifesciences Limited has informed the Exchange about Completion of USFDA Inspection
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Cohance Lifesciences dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Cohance Lifesciences has declared, sequenced by announce and record date.
Cohance Lifesciences corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Cohance Lifesciences insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Cohance Lifesciences as reported to SEBI — buying and selling signals from the people who know the business best.
Cohance Lifesciences insider activity below tracks 2 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Jusmiral Holdings Limited | Insider | 09 May 2025 | buy | +12.65 Cr | ₹12.65 Cr. | ₹1.00 |
| Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri | Insider | 09 May 2025 | buy | +7.13 L | ₹7.13 L | ₹1.00 |
About Cohance Lifesciences Limited: business, sector, key facts.
What Cohance Lifesciences Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Cohance Lifesciences Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: COHANCE, BSE: 543064.
Cohance Lifesciences Limited is an Indian contract development and manufacturing organization (CDMO) specializing in the pharmaceutical industry. Their core business revolves around providing comprehensive services throughout the entire drug development and manufacturing process, from the initial stages of creating intermediate compounds and active pharmaceutical ingredients (APIs) to the final production of finished dosage formulations (FDFs).
A significant portion of Cohance's business is centered around its CDMO services. This encompasses offering flexible and customized solutions designed to meet the unique and often complex development and manufacturing requirements of its clients. They cater to companies needing assistance with various aspects of drug production, allowing for tailored approaches to challenges encountered during the drug lifecycle.
Beyond CDMO services, Cohance produces and supplies APIs and FDFs for a wide range of pharmaceutical applications. This direct manufacturing capability complements their CDMO services, offering clients a complete spectrum of pharmaceutical production capabilities, from basic building blocks to final consumer-ready products. Their API offerings extend beyond pharmaceuticals; they also manufacture specialty chemicals, such as those used in the electronics industry.
Supporting their core manufacturing and development functions, Cohance provides a suite of analytical, clinical, and research services. These services likely support internal processes as well as offer additional services to clients, furthering their role as a comprehensive partner for pharmaceutical development. The integrated nature of these services underlines their commitment to a holistic approach in servicing the pharmaceutical industry.
Established in 1989 and based in Hyderabad, India, Cohance (formerly Suven Pharmaceuticals Limited) is a subsidiary of Berhyanda Limited. The company's long history and presence in India's pharmaceutical sector positions it as a significant player in the global CDMO landscape. Their diverse offerings and commitment to customized solutions underscore their efforts to cater to the evolving needs of the pharmaceutical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Cohance Lifesciences Limited (COHANCE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Cohance Lifesciences Limited (COHANCE)?
The current share price of Cohance Lifesciences Limited (COHANCE) is ₹463.00. Today, the stock has declined by ₹12.55 (2.64%), trading in a range of ₹457.00 to ₹481.05. The stock opened at ₹477.90 with a trading volume of 16,38,869 shares.
02Is Cohance Lifesciences Limited stock a good investment for long-term?
Cohance Lifesciences Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹17,743.46 Cr., P/E ratio of 167.27, ROE of 7.04%, and ROCE of 8.35%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Cohance Lifesciences Limited stock?
The 52-week high price of Cohance Lifesciences Limited (COHANCE) is ₹1,038.90, while the 52-week low is ₹266.70. Currently trading at ₹463.00, the stock is 73.6% above its 52-week low and 55.43% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Cohance Lifesciences Limited stock at the current price?
Whether to buy Cohance Lifesciences Limited stock at ₹463.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 167.27 and P/B ratio of 4.55. Today's performance shows a loss of 2.64%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Cohance Lifesciences Limited and when is the next dividend?
Cohance Lifesciences Limited offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹463.00, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Cohance Lifesciences Limited?
Cohance Lifesciences Limited's key financial metrics include: P/E Ratio: 167.27, P/B Ratio: 4.55, ROE: 7.04%, ROCE: 8.35%, Dividend Yield: 0%, EPS: ₹2.77, Book Value: ₹102.03, and Debt-to-Equity: 0.1. The company's market cap stands at ₹17,743.46 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Cohance Lifesciences Limited stock performing today in the market?
Cohance Lifesciences Limited stock opened at ₹477.90 and is currently trading at ₹463.00, showing a decline of ₹12.55 (2.64%). The intraday high is ₹481.05 and low is ₹457.00. The trading volume stands at 16,38,869 shares, indicating strong market participation today.
08What is the P/E ratio of Cohance Lifesciences Limited and what does it indicate?
Cohance Lifesciences Limited has a Price-to-Earnings (P/E) ratio of 167.27, which means investors are willing to pay 167.27 for every ₹1 of earnings. With an EPS of ₹2.77, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Cohance Lifesciences Limited (COHANCE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.